Sign in

    Carl Burns • Analyst

    Carl Burns is an equity analyst who specializes in investment research, with a particular focus on providing actionable insights for institutional and retail investors. His professional coverage areas and specific companies, quantitative performance metrics, and industry recognition could not be verified from public search results. Carl has held analyst roles in the financial sector, but details about his career timeline, previous employers, and securities licensing are also not currently available. As of now, there is no confirmation of his FINRA registration, notable achievements, or credentials due to limited publicly accessible information.

    Carl Burns's questions to TriSalus Life Sciences Inc (TLSI) leadership

    Carl Burns's questions to TriSalus Life Sciences Inc (TLSI) leadership • Q4 2024

    Question

    Carl Burns inquired about the specific clinical applications driving the uptake of the TriNav large vessel system and sought to quantify the impact of the new CMS reimbursement code for TARE mapping procedures.

    Answer

    CEO Mary Szela and Medical Director Dr. Richard Marshall explained that the TriNav large vessel system is primarily being used in TARE procedures for larger vessels and low-bar applications, particularly in patients with neuroendocrine tumors. Regarding the new CMS code for mapping, Szela clarified it applies to Medicare patients (about 25% of the market) who were previously not using TriNav for mapping due to reimbursement concerns, noting this was not baked into guidance and represents potential upside.

    Ask Fintool Equity Research AI